Edgewise Therapeutics (EWTX) Income towards Parent Company (2020 - 2026)

Edgewise Therapeutics has reported Income towards Parent Company for 7 years, with the latest figure at -$49.0 million in Q1 2026.

• Quarterly Income towards Parent Company fell 20.14% year-over-year to -$49.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$179.8 million (down 18.49% YoY) and the FY2025 annual result came in at -$423.5 million, down 5.56% from the prior year.
• Income towards Parent Company grew to -$49.0 million in Q1 2026 per EWTX's latest filing, from -$54.0 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$16.5 million in Q2 2022 and troughed at -$54.0 million in Q4 2025.
• A 5-year average of -$32.6 million and a median of -$32.6 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company sank 163.55% in 2022, then dropped 10.91% in 2025.
• Over 5 years, Income towards Parent Company stood at -$19.8 million in 2022, then tumbled by 52.14% to -$30.2 million in 2023, then plunged by 46.58% to -$44.3 million in 2024, then decreased by 22.04% to -$54.0 million in 2025, then advanced by 9.26% to -$49.0 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$49.0 million, -$54.0 million, and -$40.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.